Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EC Ecopetrol SA

Trading 12-22 13:35:14 EST

9.33

+0.12

+1.30%

High9.41	Low9.29	Vol854.39K
Open9.29	D1 Closing9.21	Amplitude1.36%
Mkt Cap19.18B	Tradable Cap2.18B	Total Shares2.06B
T/O7.98M	T/O Rate0.37%	Tradable Shares233.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EC","market":"US","secType":"STK","nameCN":"Ecopetrol SA","latestPrice":9.33,"timestamp":1766428513219,"preClose":9.21,"halted":0,"volume":854387,"delay":0,"floatShares":233420503,"shares":2055834734,"eps":1.411241,"marketStatus":"Trading","change":0.12,"latestTime":"12-22 13:35:14 EST","open":9.285,"high":9.41,"low":9.285,"amount":7975553.5544685,"amplitude":0.013572,"askPrice":9.33,"askSize":200,"bidPrice":9.32,"bidSize":700,"shortable":3,"etf":0,"ttmEps":1.411241,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":1,"adrRate":20,"listingDate":1221710400000,"exchange":"NYSE","adjPreClose":9.21,"dividendRate":0.106217,"preHourTrading":{"tag":"盘前","latestPrice":9.27,"preClose":9.21,"latestTime":"09:28 EST","volume":6115,"amount":57120.208885,"timestamp":1766413718089},"postHourTrading":{"tag":"盘后","latestPrice":9.2,"preClose":9.21,"latestTime":"18:29 EST","volume":44417,"amount":409087.5683,"timestamp":1766186985950},"volumeRatio":0.59402,"impliedVol":0.3185,"impliedVolPercentile":0.088},"requestUrl":"/m/hq/s/EC","defaultTab":"news","newsList":[{"id":"2591960306","title":"Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591960306","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591960306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:24","pubTimestamp":1765765494,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a regulatory application to the British Standards Institution for approval to commercially distribute its nerve repair product Remplir into the European Union and UK markets, according to a Monday Australian bourse filing.The regulatory approval for the required European Conformity  and UK Conformity Assessed  certifications is expected to be received in the September quarter of 2026.Its shares rose 3% in recent trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4201","BK7508","EC","OCC.AU"],"gpt_icon":0},{"id":"2590850738","title":"EU’s critical minerals strategy: €3 billion boost amid industry risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850738","media":"Fastmarkets","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590850738?lang=en_us&edition=fundamental","pubTime":"2025-12-12 13:00","pubTimestamp":1765515600,"startTime":"0","endTime":"0","summary":"On Wednesday December 3, the EU unveiled its ReSourceEU Action Plan, providing new guidance on critical raw materials supply, with a renewed emphasis on defense and $3.5 billion in funding for the coming year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/eus-critical-minerals-strategy-e3-billion-boost-amid-industry-risks/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/eus-critical-minerals-strategy-e3-billion-boost-amid-industry-risks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["BK4202","BK4129","EC","DLA","IEA","BK4156","BK4201"],"gpt_icon":0},{"id":"2590526453","title":"Press Release: Decisions of the Board of Directors of Ecopetrol S.A.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526453?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:24","pubTimestamp":1765506240,"startTime":"0","endTime":"0","summary":"BOGOTA, Colombia, Dec. 11, 2025 /PRNewswire/ -- Ecopetrol S.A.  announces that, at its board of directors meeting held on December 10 and 11, 2025, and following the previously disclosed resignations of directors Mónica de Greiff Lindo and Guillermo García Realpe, its board of directors approved the new composition of its supporting committees as follows:. On behalf of the Company, we express our sincere gratitude to Dr. Mónica de Greiff Lindo and Dr. Guillermo García Realpe for their outstanding work, dedication, and commitment during their tenure on the board of directors of Ecopetrol S.A., as well as for their distinguished service as chairs of the board during their respective terms.To Dr. de Greiff, we extend our appreciation for her remarkable role as the first female chair of the board of directors of Ecopetrol S.A. and her ability to build bridges and foster consensus.Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201"],"gpt_icon":0},{"id":"2590515385","title":"Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515385","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515385?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy --  -- Promising r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203809/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Exploratory-Phase-2-Trial-that-showed-Setmelanotide-Demonstrated-Positive-Efficacy-Signal-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","EC","VUS","PWS"],"gpt_icon":0},{"id":"2590408558","title":"Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590408558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590408558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203492/0/en/Rhythm-Pharmaceuticals-to-Announce-Preliminary-Data-from-Exploratory-Phase-2-Trial-Evaluating-Setmelanotide-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","VUS","PWS","BK4201"],"gpt_icon":0},{"id":"2588250357","title":"Ecopetrol Completes Negotiations With Grenergy for Potential Purchase of 7 Colombian Firms","url":"https://stock-news.laohu8.com/highlight/detail?id=2588250357","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588250357?lang=en_us&edition=fundamental","pubTime":"2025-12-01 18:06","pubTimestamp":1764583578,"startTime":"0","endTime":"0","summary":"Ecopetrol  said late Friday it completed negotiations with Grenergy Renovables for the potential acquisition of seven companies within its portfolio in Colombia.Each company owns the assets, licenses, agreements, and permits for a solar photovoltaic project with an estimated renewable energy generation capacity of up to 12.6 megawatt-peak per project.The company said the deal is subject to certain conditions precedent and other certain legal requirements.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","EC"],"gpt_icon":0},{"id":"2587731271","title":"CStone Pharmaceuticals (SEHK:2616) Is Up 9.7% After EC Approval for Sugemalimab in Lung Cancer—Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731271","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731271?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:15","pubTimestamp":1764346521,"startTime":"0","endTime":"0","summary":"On November 25, 2025, CStone Pharmaceuticals announced that the European Commission approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer characterized by specific genetic profiles and stable disease following platinum-based chemoradiotherapy.\nThis regulatory milestone not only broadens sugemalimab's reach into the European market, but also highlights the growing importance of targeted immunotherapies for difficult-to-treat...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-is-up-97-after-ec-approval-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-is-up-97-after-ec-approval-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EC","BK4201","BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2586078013","title":"Press Release: Updates from Ecopetrol S.A.'s Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586078013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586078013?lang=en_us&edition=fundamental","pubTime":"2025-11-28 21:53","pubTimestamp":1764337980,"startTime":"0","endTime":"0","summary":"BOGOTA, Colombia, Nov. 28, 2025 /PRNewswire/ -- Ecopetrol S.A.   announces that, during its meeting held on November 27, 2025, the board of directors elected ngela María Robledo Gómez as Chairwoman and lvaro Torres Macías as Vice Chairman of the Board.Additionally, Ecopetrol reports that, through a communication dated November 27, 2025, Dr. Guillermo García Realpe expressed his intention to resign from his position as Independent Director of the board for personal reasons. At the request of the other board members, his resignation will become effective as of December 12, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201"],"gpt_icon":0},{"id":"2586812197","title":"Ecopetrol Details 2026 Investment Plan, Flags Cost Reductions","url":"https://stock-news.laohu8.com/highlight/detail?id=2586812197","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586812197?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:03","pubTimestamp":1764331437,"startTime":"0","endTime":"0","summary":"Ecopetrol  said Thursday it plans to invest 22 trillion Colombian pesos  to 27 trillion pesos next year.Roughly 70% of the planned investment will go toward producing 730,000 to 740,000 barrels of oil equivalent per day, among other things, with the rest to be invested in energy transition and power transmission projects, as well as roads and other corporate investments.The company said the latest investment plan considers \"a challenging environment,\" with a projected Brent price of $60 a barrel. \"Accordingly, Ecopetrol Group has defined a strategy to safeguard profitability and liquidity through cost reductions,\" it said.The company expects its profitability and efficiency program to contribute roughly 5.7 trillion pesos, among other benefits, it said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","EC"],"gpt_icon":0},{"id":"2586781847","title":"Ecopetrol Appoints Angela Maria Robledo Gomez as Chairwoman","url":"https://stock-news.laohu8.com/highlight/detail?id=2586781847","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586781847?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:43","pubTimestamp":1764330207,"startTime":"0","endTime":"0","summary":"Ecopetrol (EC) said Friday it has named Angela Maria Robledo Gomez as chairwoman.The company also appointed Alvaro Torres Macias as vice chairman, it said in a regulatory filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","EC"],"gpt_icon":0},{"id":"2586320827","title":"EC Healthcare Swings to Fiscal H1 Loss as Revenue Declines 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586320827","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586320827?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:57","pubTimestamp":1764305870,"startTime":"0","endTime":"0","summary":"EC Healthcare  reported a HK$10.3 million attributable loss for the six months ended Sept. 30, compared with a HK$14.1 million profit a year earlier, according to a Friday Hong Kong bourse filing.Loss per share for the fiscal first-half came in at HK$0.009, compared with earnings of HK$0.012 in the prior-year period.Revenue fell 6.4% to HK$1.93 billion from HK$2.06 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EC","XLV","HCSG"],"gpt_icon":0},{"id":"2586081582","title":"EC Healthcare Reports Decline in Interim Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2586081582","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586081582?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:39","pubTimestamp":1764304755,"startTime":"0","endTime":"0","summary":"An announcement from EC Healthcare ( ($HK:2138) ) is now available. EC Healthcare reported its interim financial results for the six months ending ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ec-healthcare-reports-decline-in-interim-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ec-healthcare-reports-decline-in-interim-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4581","EC","BK4588","BK4137","XLV","LABU","BK4201","BK4585","XBI","LU0128526141.USD","LU0029874061.USD"],"gpt_icon":0},{"id":"1129360357","title":"CMSC: Solvent Supply-Demand and Profitability Improving, EC Solvent Shows Greater Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1129360357","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129360357?lang=en_us&edition=fundamental","pubTime":"2025-11-28 09:48","pubTimestamp":1764294506,"startTime":"0","endTime":"0","summary":"According to a research report by CMSC, the lithium battery solvent segment has seen effective supply-demand recovery in recent years amid sustained demand growth. Leading solvent producers are now...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06099","BK1147","BK0010","600999","BK0028","BK4201","BK0183","BK1564","BK0012","EC","BK0276","BK0188"],"gpt_icon":0},{"id":"2586266920","title":"EU Moves To Ease AI Regulations To Narrow US-China Tech Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266920","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266920?lang=en_us&edition=fundamental","pubTime":"2025-11-26 23:24","pubTimestamp":1764170640,"startTime":"0","endTime":"0","summary":"The European Union  has postponed key artificial intelligence and data privacy regulations until 2027, aiming to enhance its competitiveness against tech superpowers, the US and China.The decision reflects concerns among European leaders and executives that the continent's strict digital governance frameworks are constraining innovation and investment. In July, dozens of European executives called on the European Commission  to pause the EU AI Act, which governs the development and use of AI systems to ensure they are safe, transparent, and respect fundamental rights.In 2024, US firms invested roughly $109 billion in AI. That was more than 12 times China's $9.3 billion and nearly 24 times the EU's $4.5 billion, according to Stanford University.The EU's advanced technologies, such as AI and cloud computing, have fallen behind the US, the EC said in January. In generative AI, US investment exceeded the combined total of China, the EU, and the UK by $25.4 billion in 2024, according to Sta","market":"sh","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/11/49086024/eu-moves-to-ease-ai-regulations-to-narrow-us-china-tech-lead","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/11/49086024/eu-moves-to-ease-ai-regulations-to-narrow-us-china-tech-lead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2108987350.USD","IE00BQXX3C00.GBP","LU1923622614.USD","LU2279689827.SGD","LU2023250330.USD","LU1430594728.SGD","LU2764263039.SGD","LU1236620834.HKD","LU2097829019.USD","IE00B775SV38.USD","LU2471134796.USD","LU0965509010.AUD","LU1564329032.USD","SG9999014567.USD","LU1815336760.USD","EC","LU1059921491.USD","LU1084165304.USD","LU2065171402.SGD","USAW.SI","USJW.SI","LU0708994859.HKD","LU1267930227.SGD","LU0868494708.USD","LU0107464264.USD","LU1037948541.HKD","LU2211817866.USD","IE00B1BXHZ80.USD","IE00BJJMRY28.SGD","DMA","LU1934455863.HKD","LU2433249047.HKD","IE000KEQY171.SGD","LU2487616109.SGD","LU2381873111.SGD","LU1989773731.SGD","LU1699723380.USD","LU2543165471.USD","LU0545562505.USD","AI","SG9999015952.SGD","LU0124676726.USD","LU0314106906.USD","LU0198837287.USD","IE00B19Z8W00.USD"],"gpt_icon":1},{"id":"2586628532","title":"Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2586628532","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586628532?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:06","pubTimestamp":1764119160,"startTime":"0","endTime":"0","summary":"SINGAPORE, Nov. 26, 2025 /PRNewswire/ --Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue  across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.Tuznue is a biosimilar to Herceptin , approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received European Commission  marketing authorization for Tuznue in September 2024. This approval marks a major milestone for the company's biosimilar portfolio, signaling progress in expanding access to cost-effective treatments across key global markets.Under the agreement, Biosidus secures exclusive rights to market and distribute Tuznue in Argentina, Mexico, Bolivia, and Paraguay, leveraging its exte","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-and-biosidus-enter-exclusive-license-agreement-for-tuznue-commercialization-in-latin-america-302626222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","MGC","MBC","BK4007","MGC.AU","PBH","BK4211","BK4086","EBC","BK4201"],"gpt_icon":1},{"id":"2586755564","title":"Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®","url":"https://stock-news.laohu8.com/highlight/detail?id=2586755564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586755564?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:10","pubTimestamp":1764076200,"startTime":"0","endTime":"0","summary":"Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194303/0/en/Teva-receives-European-Commission-approvals-for-PONLIMSI-denosumab-Biosimilar-to-Prolia-and-DEGEVMA-denosumab-Biosimilar-to-Xgeva.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4087","BK4201","EC"],"gpt_icon":0},{"id":"2586441814","title":"Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586441814","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586441814?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:00","pubTimestamp":1764050400,"startTime":"0","endTime":"0","summary":"Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194013/0/en/Dupixent-dupilumab-Approved-as-the-First-Targeted-Medicine-in-the-European-Union-EU-in-Over-a-Decade-for-Chronic-Spontaneous-Urticaria-CSU.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4096","LU1974910355.USD","LU0114720955.EUR","LU1917777945.USD","IE00BFXG1179.USD","LU0823416689.USD","LU2362540622.SGD","LU2106854487.HKD","REGN","LU2237438978.USD","LU2023250504.SGD","LU2362541513.USD","SNY","BK4156","LU2468319806.SGD","BP","LU0823434583.USD","LU0882574055.USD","LU2362541273.HKD","BK4585","LU0072461881.USD","LU1162221912.USD","LU0289739699.SGD","LU0053666078.USD","BK4139","LU0162691827.USD","EC","LU0109394709.USD","BK4007","BK4588","LU0889565916.HKD","PN","LU1829250122.USD","LU2089984988.USD","BK4201","LU0823434740.USD","LU0320765646.SGD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2586413910","title":"Bristol Myers says EC grants approval to Breyanzi for treatment of MCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2586413910","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586413910?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:05","pubTimestamp":1764021918,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T cel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-says-ec-grants-approval-to-breyanzi-for-treatment-of-mcl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-says-ec-grants-approval-to-breyanzi-for-treatment-of-mcl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0321505868.SGD","BK4126","LU1868836914.USD","BK4007","IE0009355771.USD","BK4588","LU0225284248.USD","LU1571399168.USD","LU1670710661.SGD","BK4532","LU1585245621.USD","LU0306806265.USD","LU1868836591.USD","LU0985481810.HKD","LU0061475181.USD","LU1093756168.USD","BK4534","EC","LU2242646821.SGD","LU0237698245.USD","LU2133065610.SGD","LU1868837300.USD","LU1670711040.USD","BMY","LU1291159041.SGD","LU2125154778.USD","IE00BJJMRZ35.SGD","MYE","LU0114720955.EUR","LU1323610961.USD","LU2360032135.SGD","BK4559","LU0456855351.SGD","BK4201","LU0321505439.SGD","LU1989771016.USD","BK4585","IE00B2B36J28.USD","LU1868836757.USD","LU1868837136.USD","LU1718418525.SGD","BK4581","LU2125154935.USD","LU0868494617.USD","IE00BSNM7G36.USD","LU0306807586.USD","LU1093756325.SGD","LU1670710588.SGD","LU1670711123.USD"],"gpt_icon":0},{"id":"2585049306","title":"Omnicom, Interpublic Group receive unconditional clearance from EC","url":"https://stock-news.laohu8.com/highlight/detail?id=2585049306","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585049306?lang=en_us&edition=fundamental","pubTime":"2025-11-24 23:05","pubTimestamp":1763996723,"startTime":"0","endTime":"0","summary":"Omnicom Group (OMC) and The Interpublic Group of Companies (IPG) announced that the European Commission has granted antitrust approval for Omnicom’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omnicom-interpublic-group-receive-unconditional-clearance-from-ec-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omnicom-interpublic-group-receive-unconditional-clearance-from-ec-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1599440770.SGD","LU1481011911.USD","LU0648000940.SGD","LU1481011671.HKD","BK4585","LU0130103400.USD","LU1509826696.USD","EC","LU0321505439.SGD","OMC","LU1201861165.SGD","BK4588","IPG","LU0772969993.USD","LU0731783048.USD","BK4009","LU0731783394.SGD","LU0742537680.HKD","BK4201","LU0130518102.USD","LU0321505868.SGD","LU0477156797.USD"],"gpt_icon":0},{"id":"2585469354","title":"Waters Proposed Acquisition of Becton, Dickinson's Biosciences, Diagnostic Operations Gets EC's Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2585469354","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585469354?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:33","pubTimestamp":1763983980,"startTime":"0","endTime":"0","summary":"Waters  proposed acquisition of Becton, Dickinson and Company's  biosciences and diagnostic services operations has received the European Commission's approval, the regulator said Monday.The transaction would \"not raise competition concerns\" as the two companies are not active in the same or vertically related industries, the Commission said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0130518102.USD","LU0985320562.USD","LU0130103400.USD","WAT.AU","LU0648000940.SGD","LU0347712357.USD","LU1571399168.USD","BK7067","LU0289961442.SGD","LU1721428933.USD","GB00B4QBRK32.GBP","LU0162691827.USD","LU1489326972.SGD","BK4082","BK4201","IE00BFXG1179.USD","LU2404859741.USD","LU2413666699.HKD","LU1894683264.USD","LU0878866978.SGD","LU0068578508.USD","BDX.AU","GB00B4LPDJ14.GBP","LU2413666426.HKD","EC","LU1894683348.USD","WAT","LU0690374615.EUR","LU0690374961.EUR","LU0006061336.USD","BDX","LU1150488218.USD","LU1854104046.USD","BK4121","LU1059921491.USD","LU2404859667.USD","BK4585","LU0266013472.USD","BK4504","LU1201861165.SGD","BK7118","LU1150488135.SGD","LU0289739343.SGD","LU0433182093.SGD","BK4588","LU0985489474.SGD","LU0072461881.USD","LU0477156797.USD","LU0511384066.AUD","LU1854103824.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ecopetrol.com.co","stockEarnings":[{"period":"1week","weight":-0.0534},{"period":"1month","weight":-0.1178},{"period":"3month","weight":0.0372},{"period":"6month","weight":-0.064},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.1629}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ecopetrol S.A. operates as an integrated energy company. The company operates through four segments: Exploration and Production; Transport and Logistics; Refining, Petrochemical and Biofuels; and Electric Power Transmission and Toll Roads Concessions. It engages in the exploration and production of oil and gas; transportation of crude oil, motor fuels, fuel oil, and other refined products, including diesel, jet, and biofuels; processing and refining crude oil; distribution of natural gas and LPG; sale of refined and petrochemical products; supplying of electric power transmission services; design, development, construction, operation, and maintenance of road and energy infrastructure projects; and supplying of information technology and telecommunications services. As of December 31, 2022, the company had approximately 9,127 kilometers of crude oil and multi-purpose pipelines. It also produces and commercializes polypropylene resins and compounds, and masterbatches; and offers industrial service sales to customers and specialized management services. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, and South America. The company was formerly known as Empresa Colombiana de Petróleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was incorporated in 1948 and is headquartered in Bogotá, Colombia.","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.035816},{"month":2,"riseRate":0.529412,"avgChangeRate":0.016842},{"month":3,"riseRate":0.705882,"avgChangeRate":0.021845},{"month":4,"riseRate":0.470588,"avgChangeRate":-0.009586},{"month":5,"riseRate":0.352941,"avgChangeRate":-0.016936},{"month":6,"riseRate":0.470588,"avgChangeRate":0.005743},{"month":7,"riseRate":0.470588,"avgChangeRate":0.007592},{"month":8,"riseRate":0.470588,"avgChangeRate":0.000807},{"month":9,"riseRate":0.470588,"avgChangeRate":-0.011239},{"month":10,"riseRate":0.611111,"avgChangeRate":-0.007073},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.030395},{"month":12,"riseRate":0.555556,"avgChangeRate":0.005392}],"exchange":"NYSE","name":"Ecopetrol SA","nameEN":"Ecopetrol SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ecopetrol SA,EC,Ecopetrol SA股票,Ecopetrol SA股票老虎,Ecopetrol SA股票老虎国际,Ecopetrol SA行情,Ecopetrol SA股票行情,Ecopetrol SA股价,Ecopetrol SA股市,Ecopetrol SA股票价格,Ecopetrol SA股票交易,Ecopetrol SA股票购买,Ecopetrol SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction